Goldmann L, Duan R, Kragh T, et al. Oral Bruton tyrosine kinase inhibitors block activation of the platelet Fc receptor CD32a (FcγRIIA): a new option in HIT? Blood Adv. 2019;3(23):4021-4033.

Benzer Materyaller

• Oral Bruton tyrosine kinase inhibitors block activation of the platelet Fc receptor CD32a (FcγRIIA): a new option in HIT?
  Yazar:: Goldmann, Luise, ve diğerleri
  Baskı/Yayın Bilgisi: (2019)
• Association of FCγRIIA (CD32) polymorphism with susceptibility to brucellosis
  Yazar:: Zahra Hosseini khah, ve diğerleri
  Baskı/Yayın Bilgisi: (2014-08-01)
• Bruton’s Tyrosine Kinase Mediates FcγRIIa/Toll-Like Receptor–4 Receptor Crosstalk in Human Neutrophils
  Yazar:: Krupa, Agnieszka, ve diğerleri
  Baskı/Yayın Bilgisi: (2013)
• Meningococcal disease and polymorphism of FcγRIIa (CD32) in late complement component-deficient individuals
  Yazar:: Platonov, A E, ve diğerleri
  Baskı/Yayın Bilgisi: (1998)
• Engineered antibody Fc variant with selectively enhanced FcγRIIb binding over both FcγRIIa(R131) and FcγRIIa(H131)
  Yazar:: Mimoto, F., ve diğerleri
  Baskı/Yayın Bilgisi: (2013)